JP2007509994A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509994A5 JP2007509994A5 JP2006538688A JP2006538688A JP2007509994A5 JP 2007509994 A5 JP2007509994 A5 JP 2007509994A5 JP 2006538688 A JP2006538688 A JP 2006538688A JP 2006538688 A JP2006538688 A JP 2006538688A JP 2007509994 A5 JP2007509994 A5 JP 2007509994A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- group
- hydroxy
- alkyl
- acyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 28
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 21
- 125000002252 acyl group Chemical group 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 125000001424 substituent group Chemical group 0.000 claims description 16
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 15
- 229920006395 saturated elastomer Polymers 0.000 claims description 15
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 15
- 229940045145 uridine Drugs 0.000 claims description 15
- QQHJDPROMQRDLA-UHFFFAOYSA-N hexadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCC(O)=O QQHJDPROMQRDLA-UHFFFAOYSA-N 0.000 claims description 14
- BNJOQKFENDDGSC-UHFFFAOYSA-N octadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCCC(O)=O BNJOQKFENDDGSC-UHFFFAOYSA-N 0.000 claims description 12
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 claims description 10
- -1 Palmitoyl uridine Chemical compound 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 10
- 150000002367 halogens Chemical group 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 229940116918 octadecenedioic acid Drugs 0.000 claims description 8
- SBLKVIQSIHEQOF-UPHRSURJSA-N Octadec-9-ene-1,18-dioic-acid Chemical compound OC(=O)CCCCCCC\C=C/CCCCCCCC(O)=O SBLKVIQSIHEQOF-UPHRSURJSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 239000005549 deoxyribonucleoside Substances 0.000 claims description 7
- 239000002342 ribonucleoside Substances 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229940114072 12-hydroxystearic acid Drugs 0.000 claims description 5
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims description 5
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 5
- 235000021314 Palmitic acid Nutrition 0.000 claims description 5
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 5
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 5
- 125000001142 dicarboxylic acid group Chemical group 0.000 claims description 5
- 125000005313 fatty acid group Chemical group 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 125000001166 thiolanyl group Chemical group 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 125000005358 mercaptoalkyl group Chemical group 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 3
- 239000002777 nucleoside Substances 0.000 claims description 3
- 125000003835 nucleoside group Chemical group 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical group [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- WLUVMCVVZFZLHW-OTUUDDROSA-N [(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hexadecanoate Chemical compound O[C@@H]1[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C(=O)NC(=O)C=C1 WLUVMCVVZFZLHW-OTUUDDROSA-N 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 claims 4
- 229940038384 octadecane Drugs 0.000 claims 2
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 8
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 6
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 6
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 5
- UGAGPNKCDRTDHP-UHFFFAOYSA-N 16-hydroxyhexadecanoic acid Chemical compound OCCCCCCCCCCCCCCCC(O)=O UGAGPNKCDRTDHP-UHFFFAOYSA-N 0.000 description 4
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 4
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 4
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 4
- 235000019136 lipoic acid Nutrition 0.000 description 4
- 229960002663 thioctic acid Drugs 0.000 description 4
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 4
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 3
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- GWOLZNVIRIHJHB-UHFFFAOYSA-N 11-mercaptoundecanoic acid Chemical compound OC(=O)CCCCCCCCCCS GWOLZNVIRIHJHB-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N caffeic acid Chemical compound OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 235000013985 cinnamic acid Nutrition 0.000 description 2
- 229930016911 cinnamic acid Natural products 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 235000001785 ferulic acid Nutrition 0.000 description 2
- 229940114124 ferulic acid Drugs 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 2
- HCDTXHKYVRUKRL-VBCUVWSKSA-N 1-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-octadecanoyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1=CC(=O)NC(=O)N1[C@]1(C(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@H]1O HCDTXHKYVRUKRL-VBCUVWSKSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- ZYAZNRLUURTTGE-HALQFCHDSA-N O[C@@H]1[C@H](O)[C@@H](CO)O[C@]1(N1C(NC(=O)C=C1)=O)C(=O)CCC1=CC=CC=C1 Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@]1(N1C(NC(=O)C=C1)=O)C(=O)CCC1=CC=CC=C1 ZYAZNRLUURTTGE-HALQFCHDSA-N 0.000 description 1
- PTFFISQXBOVKFP-QMDPVJEQSA-N O[C@@H]1[C@H](O)[C@@H](COCCCCCCCC\C=C/CCCCCCCC)O[C@H]1N1C(=O)NC(=O)C=C1 Chemical compound O[C@@H]1[C@H](O)[C@@H](COCCCCCCCC\C=C/CCCCCCCC)O[C@H]1N1C(=O)NC(=O)C=C1 PTFFISQXBOVKFP-QMDPVJEQSA-N 0.000 description 1
- CFZHBHZZXYXCQR-JLZPKONASA-N [(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@H]1N1C(=O)NC(=O)C=C1 CFZHBHZZXYXCQR-JLZPKONASA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03292735 | 2003-11-03 | ||
| PCT/EP2004/011990 WO2005049633A1 (en) | 2003-11-03 | 2004-10-23 | Acyl ribonucleosides and acyl deoxyribonucleosides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007509994A JP2007509994A (ja) | 2007-04-19 |
| JP2007509994A5 true JP2007509994A5 (enExample) | 2007-12-06 |
Family
ID=34610139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538688A Withdrawn JP2007509994A (ja) | 2003-11-03 | 2004-10-23 | アシルリボヌクレオシドおよびアシルデオキシリボヌクレオシド |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070160554A1 (enExample) |
| EP (1) | EP1680435A1 (enExample) |
| JP (1) | JP2007509994A (enExample) |
| KR (1) | KR20060092242A (enExample) |
| WO (1) | WO2005049633A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101111020B1 (ko) * | 2006-07-04 | 2012-03-13 | 주식회사 알엔에스 | 신규한 사이클릭 화합물의 유도체 및 그의 용도 |
| CA2717788A1 (en) | 2007-07-09 | 2009-01-15 | Eastern Virginia Medical School | Substituted nucleoside derivatives with antiviral and antimicrobial properties |
| EP2964763B1 (en) * | 2013-03-08 | 2019-09-18 | Yale University | Compositions and methods for reducing skin pigmentation |
| WO2015061507A1 (en) * | 2013-10-23 | 2015-04-30 | Chemgenes Corporation | Dithiolane functionalized nucleoside amidites and supports for stronger immobilization of bio-molecules on solid surfaces |
| SG11201705069YA (en) | 2014-12-26 | 2017-07-28 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| PL3706762T3 (pl) | 2017-12-07 | 2025-02-10 | Emory University | N4-hydroksycytydyna i pochodne oraz związane z nimi zastosowania przeciwwirusowe |
| CN110054629A (zh) * | 2019-03-27 | 2019-07-26 | 广东萱嘉医品健康科技有限公司 | 一种杜鹃花酸生物碱离子盐及其制备方法与应用 |
| AU2021202658A1 (en) | 2021-04-28 | 2022-11-17 | Fondazione Telethon | Gene therapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1297398A (enExample) * | 1969-08-06 | 1972-11-22 | ||
| US6348451B1 (en) * | 1987-10-28 | 2002-02-19 | Pro-Neuron, Inc. | Acyl deoxyribonucleoside derivatives and uses thereof |
| US5470838A (en) * | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
| CA1321994C (en) * | 1987-10-28 | 1993-09-07 | Reid Von Borstel | Acylated uridine and cytidine and uses thereof |
| WO1991006555A1 (fr) * | 1989-10-26 | 1991-05-16 | Yamasa Shoyu Kabushiki Kaisha | Derive nucleosidique |
| GB9515279D0 (en) * | 1995-07-25 | 1995-09-20 | Norsk Hydro As | Improved therapeutic agents |
| GB9307043D0 (en) * | 1993-04-05 | 1993-05-26 | Norsk Hydro As | Chemical compounds |
| ES2327397T3 (es) * | 2001-04-30 | 2009-10-29 | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL | Esteres de uridina farmaceuticamente activos. |
-
2004
- 2004-10-23 EP EP04790781A patent/EP1680435A1/en not_active Withdrawn
- 2004-10-23 WO PCT/EP2004/011990 patent/WO2005049633A1/en not_active Ceased
- 2004-10-23 US US10/595,656 patent/US20070160554A1/en not_active Abandoned
- 2004-10-23 KR KR1020067006637A patent/KR20060092242A/ko not_active Withdrawn
- 2004-10-23 JP JP2006538688A patent/JP2007509994A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0606012B1 (en) | Compositions containing cholesteryl esters of unsaturated fatty acids | |
| KR100309194B1 (ko) | 항바이러스화합물 | |
| DE60314633T2 (de) | Substituierte 1,3-diphenylprop-2-en-1-on derivate, deren herstellung und anwendungen | |
| FI91764B (fi) | Analogiamenetelmä asyylideoksiribonukleosidijohdannaisten valmistamiseksi | |
| AU743136B2 (en) | Medical uses of pyruvates | |
| AU2025202961A1 (en) | Compositions and methods for modulating hair growth | |
| US7396826B2 (en) | Pharmaceutically active uridine esters | |
| PL209031B1 (pl) | Estry urydyny, ich zastosowanie i sposób wytwarzania, oraz kompozycje farmaceutyczne je zawierające | |
| EP0056265B1 (de) | 5'-Ester von Pyrimidinnucleosiden mit antiviraler Wirksamkeit, Verfahren zur Herstellung und daraus hergestellte Arzneimittel | |
| JP2007509994A5 (enExample) | ||
| JP5552314B2 (ja) | 新規脂質化合物 | |
| AU2019418584A1 (en) | Compositions and methods for modulating hair growth | |
| DE60301878T2 (de) | Pharmazeutische zusammensetzung enthaltend ein alpha-ketoalkansäureester oder -amid und milchsäure oder ein milchsäuresalz | |
| JPS5857397A (ja) | 安定なｓ−アデノシルメチオニン誘導体、その製法及びそれを活性成分として含む治療用組成物 | |
| WO1995034303A1 (en) | Method for the treatment, prevention or minimization of hair loss | |
| PT98121B (pt) | Processo para a preparacao de novos 3,3'-ditio-bis (acidos propionicos) e seus esteres e de composicoes farmaceuticas que os contem | |
| WO2018132759A1 (en) | Compounds and methods use | |
| JP2013522289A (ja) | シトシン類似体、シトシン類似体の調製方法、ｄｎａメチルトランスフェラーゼ１阻害剤、ｄｎａメチル化の阻害方法、正常なｄｎａメチル化からの逸脱と関連する疾患の治療における類似体の使用 | |
| JP2007509994A (ja) | アシルリボヌクレオシドおよびアシルデオキシリボヌクレオシド | |
| WO2018183353A1 (en) | Small molecule compounds to support healthy human aging | |
| EP1587508A1 (fr) | Utilisation therapeutique d 'acylglycerols et de leurs analogues azotes et sulfures | |
| US20050267187A1 (en) | Process of preparing esters and ethers of probucol and derivatives thereof | |
| CA2515680A1 (fr) | Aminopropanediols acyles et analogues et leurs utilisations therapeutiques | |
| Dumont | Glyceride conjugates as drug carriers | |
| WO1995026719A1 (en) | Method for delivering biologically active materials using a thioester or thioether prodrug |